Harmony Biosciences Holdings Inc (HRMY)
29.23
+0.38
(+1.32%)
USD |
NASDAQ |
Apr 24, 16:00
29.21
-0.02
(-0.07%)
After-Hours: 20:00
Harmony Biosciences Holdings Revenue (TTM): 582.02M for Dec. 31, 2023
Revenue (TTM) Chart
Historical Revenue (TTM) Data
| Date | Value |
|---|---|
| December 31, 2023 | 582.02M |
| September 30, 2023 | 541.92M |
| June 30, 2023 | 498.86M |
| March 31, 2023 | 471.67M |
| December 31, 2022 | 437.86M |
| September 30, 2022 | 400.76M |
| June 30, 2022 | 364.29M |
| Date | Value |
|---|---|
| March 31, 2022 | 331.08M |
| December 31, 2021 | 305.44M |
| September 30, 2021 | 270.52M |
| June 30, 2021 | 235.39M |
| March 31, 2021 | 199.58M |
| December 31, 2020 | 159.74M |
| September 30, 2020 | 109.45M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (TTM) Range, Past 5 Years
109.45M
Minimum
Sep 2020
582.02M
Maximum
Dec 2023
350.61M
Average
347.68M
Median
Revenue (TTM) Benchmarks
| Amylyx Pharmaceuticals Inc | 380.79M |
| Exelixis Inc | 1.830B |
| Insmed Inc | 305.21M |
| Arcturus Therapeutics Holdings Inc | 157.75M |
| Ultragenyx Pharmaceutical Inc | 434.25M |